
ESC 2026: Pacibekitug (IL-6 ligand mAb) in patients with CKD and high CV risk
۳۰ مهر ۱۴۰۵ · 6 دقیقه
📚 ESC 2026 coverage: Can targeting IL-6 with pacibekitug reduce residual inflammatory risk in patients with CKD and high cardiovascular risk? by Dr. Mohammadi, clinical pharmacist.
















